N/A N=24 The Monitoring Study
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region — 0.0015; 0.0034; -0.0204; -0.0293 ratio
Phase 3 N=343 A Study For Pregabalin In Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14 — -2.01; -1.28 Units on a scale — p=0.0001
Phase 3 N=1,146 Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Irritable Bowel Syndrome
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores — 28.9…
Phase 3 N=3,005 Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Migraine With or Without Aura
Primary: Percentage of Participants Headache Pain Free at 2 Hours Post Dose — 28.6; 31.4; 38.8; 21.3 percentage of participants — p=0.003
Phase 4 N=50 Switch to Unboosted Atazanavir With Tenofovir Study
HIV Infection
Primary: Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm — 2; 6 Participants
Phase 1 N=12 Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Leukemia · Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
N/A N=66 Text Messaging for Supporting Quit Attempts
Tobacco Use Cessation · Tobacco Use Disorder
Primary: Self Reported Smoking Abstinence — 11; 2 Participants
N/A N=200 CoreValve Advance-II Study: Prospective International Post-market Study
Aortic Valve Stenosis · Valvular Heart Disease
Primary: New-onset Class I or II Indication for Permanent Pacemaker Implantation — 13.3; 21.4 Percentage of subjects
Phase 2 N=58 Lutropin Alfa in Women at Risk of Poor Response
Ovarian Stimulation
Primary: Number of Oocytes Retrieved — 4.0; 3.5 Oocytes
N/A N=1,217 Effects of Self-efficacy, Planning, and Self-efficacy+Planning Interventions on Body Fat Among Adolescents
Adolescent Behavior
Primary: Body Fat Tissue — 21.12; 21.99; 21.69; 21.81 percentage of body fat
N/A N=12 A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia
Postoperative Complications · Hip Fracture · Delirium
Primary: Number of Participants With Postoperative Delirium After Hip Fracture Surgery — 2; 0 Participants
Phase 4 N=51 Phase IV O2 Consumption Study in COPD Patients.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Oxygen Consumption (VO2; Obtained Via a Metabolic Cart) — 11.366; 1.252 mL/min — p=0.007
N/A N=700 Ulipristal Emergency Contraception Used Before or After Ovulation
Contraception
Primary: Percentage of Pregnancies Prevented (PPP) — 77.5; 36.9 percentage of pregnancies prevented — p=<0.0001
Phase 2 N=150 Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
Geographic Atrophy · Age-related Macular Degeneration
Primary: Part A: Geographic Atrophy (GA) Lesion Growth Measured by Fundus Autofluorescence (FAF) From Baseline to Day 505 — 1.95; 1.58 mm^2